Plexiform Fibrohistiocytic Tumor: An Updated Review Authors: JUN NISHIO, KAORI KOGA, MIKIKO AOKI Published: 2026 ABSTRACT Plexiform fibrohistiocytic tumor (PFHT) is a rare locally aggressive and rarely metastasizing mesenchymal neoplasm that most commonly arises in the upper extremities of children and young adults. It typically presents as a small, slow-growing, painless, dermal or subcutaneous mass. Magnetic resonance imaging (MRI) often reveals a plaque-like or infiltrative lesion with intermediate signal intensity on T1-weighted sequences and high signal intensity on T2-weighted sequences. Contrast-enhanced MRI demonstrates moderate or avid enhancement. Histologically, PFHT is characterized by a multinodular or plexiform proliferation of a variable admixture of histiocyte-like cells, osteoclast-like giant cells and elongated spindle cells. Immunohistochemically, the histiocyte-like and osteoclast-like giant cells express CD68, CD163 and CD11c, whereas the spindle cells are focally positive for smooth muscle actin. Most notably, cyclin D1 immunostaining demonstrates nuclear expression in the histiocyte-like and osteoclast-like giant cells as well as spindle cells. Wide local excision with long-term follow-up is generally considered optimal management for conventional cases. This review provides an updated overview of the clinical, radiological, histological, immunohistochemical, cytogenetic and molecular genetic features of PFHT and discusses the differential diagnosis of this enigmatic neoplasm. Introduction Plexiform fibrohistiocytic tumor (PFHT), first described by Enzinger and Zhang (1) in 1988, is a rare mesenchymal neoplasm of intermediate malignancy. It belongs to the so-called fibrohistiocytic tumor group according to the latest World Health Organization classification of soft tissue and bone tumors (2), with a distinctive biphasic morphology. The etiology of this peculiar tumor is unknown. The histology of PFHT can overlap with a variety of mesenchymal neoplasms, including cellular neurothekeoma, giant cell tumor of soft tissue and plexiform myofibroblastoma. Accurate diagnosis of PFHT is critical for appropriate clinical management. This review provides valuable insights into the clinical, radiological, histological, immunohistochemical, cytogenetic and molecular genetic features of PFHT. In addition, we discuss the differential diagnosis of this unusual entity. Clinical Features PFHT can occur over a wide age range but most commonly affects children and young adults, with a median age of 14.5-21 years (1, 3-5) and a female predominance (1, 4-8). A few cases of congenital PFHT have also been described (9-13). PFHT most frequently occurs in the upper extremities (50%), followed by the lower extremities (20%), trunk (16%) and head and neck (14%) (8). A single case of intraosseous PFHT in the distal diaphysis of the fibula has also been reported (14). PFHT presents as a slow-growing, painless, poorly demarcated dermal or subcutaneous nodule or mass that may elevate the overlying skin, usually measuring less than 3 cm in diameter. Occasional cases display a central dimpling (1). The median preoperative duration is 6-12 months (5, 9). The natural history of PFHT is not entirely understood (4); to date, there has been no evidence of potential spontaneous healing. Radiological Features The radiological description of PFHT is very limited in the literature (15-18). Radiographs are typically normal or may reveal soft-tissue swelling without calcification (15). Ultrasonography may show a small, hypoechoic mass with some vascular flow (15). On magnetic resonance imaging (MRI), PFHT usually manifests as a plaque-like or infiltrative lesion and exhibits intermediate signal intensity on T1-weighted sequences and high signal intensity on T2-weighted sequences. Contrast-enhanced MRI demonstrates moderate or avid enhancement (15). Follow-up chest imaging may be considered to assess for possible pulmonary metastasis, especially in younger female patients (8). Histological and Immunohistochemical Features The definitive diagnosis of PFHT is made based on histological examination supplemented with immunohistochemistry. Grossly, PFHT appears as a multinodular, poorly circumscribed mass with a gray-white to tan cut surface (1). Histologically, PFHT shows an infiltrative architecture with overall plexiform outlines and consists of small nodules of mononuclear histiocyte-like cells and osteoclast-like giant cells, surrounded by fascicles of elongated spindle cells in variable proportions (2). Three histological subtypes have been described based on the predominant cells: histiocytic, fibroblastic and mixed (1, 3). A chronic inflammatory infiltrate around the nodules is often observed (1). Myxoid or hyalinized stromal changes may be found (3, 19-22). Lymphovascular invasion is rarely seen (2). Mitotic activity is generally low and necrosis is typically absent. Immunohistochemically, the histiocyte-like and osteoclast-like cells are positive for CD68, CD163 and CD11c (4), whereas the spindle cells are focally positive for smooth muscle actin (SMA) (3, 9). Interestingly, Wang et al. (5) reported that expression of cyclin D1 (CCND1) and CD10 were found in all cases examined. The authors suggested that immunohistochemistry for CCND1 and CD10 might be a useful adjunct tool for the diagnosis of PFHT, particularly in more challenging cases. Immunostainings for cytokeratin, desmin, S100, factor XIIIa and CD34 are typically negative (1, 3, 5, 7). The Ki-67 labeling index is variable, ranging from 5% to 40% (4, 5). Cytogenetic and Molecular Genetic Features Clonal chromosomal aberrations have been detected in three cases of PFHT (23-25). PFHT displays mostly simple karyotypes characterized by one or few chromosomal rearrangements or numerical aberrations. Interestingly, one case showed a t(4;15)(q21;q15) translocation as the sole anomaly (24). To date, no consistent chromosomal alterations have been found in PFHT. On the other hand, fluorescence in situ hybridization and array-comparative genomic hybridization analyses did not identify any numerical or quantitative genomic anomaly (25). Moreover, molecular genetic analyses failed to detect significant mutations or fusion events (4). Further studies are required to elucidate the characteristic cytogenetic/molecular alterations associated with PFHT. Recently, Thangalah et al. (4) identified colony stimulating factor 1 (CSF1) mRNA expression in a subset of the mononuclear cells (“null cells”) within the histiocytoid nodules using chromogenic in situ hybridization. The authors suggested that CSF1 production by these cells might result in recruitment of non-neoplastic histiocytes and osteoclast-like giant cells to the histiocytoid nodules. Treatment and Prognosis Wide local excision is the mainstay of treatment for PFHT. When logistically feasible, Mohs micrographic surgery may be considered for the treatment of PFHT (26), especially in cosmetically sensitive or functionally critical areas. In larger series, local recurrence occurs in 10.3-40% of cases (1, 4, 5, 7, 9). Although rare, lymph node and distant metastases have been reported in the literature (1, 7, 15, 27-29). There was a single case of PFHT with systemic metastasis that resulted in the patient’s death (27). However, the overall prognosis is generally favorable after complete excision. At present, clinical or histological features are not predictive of outcome. Long-term follow-up is necessary to detect any local recurrence or nodal and pulmonary metastases. Differential Diagnosis The major differential diagnosis of PFHT includes cellular neurothekeoma, giant cell tumor of soft tissue and plexiform myofibroblastoma. These entities display a plexiform or multinodular growth pattern and are frequently confused in routine diagnostic pathology, especially in small biopsy specimens. It is important to differentiate these tumors because they have distinct clinical courses. The corresponding clinicopathological and molecular characteristics are summarized in Table I. Table IDifferential diagnosis of plexiform fibrohistiocytic tumor.PFHT: Plexiform fibrohistiocytic tumor; CNTK: cellular neurothekeoma; GCTST: giant cell tumor of soft tissue; PM: plexiform myofibroblastoma; LRR: local recurrence rate; LR: local recurrence; IHC: immunohistochemistry; SMA: smooth muscle actin; CCND1: cyclin D1; NSE: neuron-specific enolase; MiTF: microphthalmia transcription factor; PGP9.5: protein gene product 9.5; PRAME: preferentially expressed antigen in melanoma; TFE3: transcription factor E3; MTAP: methylthioadenosine phosphorylase; CDKN2A: cyclin dependent kinase inhibitor 2A; H3-3A: H3.3 histone A; SH3PXD2B: SH3 and PX domains 2B; FER: FER tyrosine kinase. Differential diagnosis of plexiform fibrohistiocytic tumor. PFHT: Plexiform fibrohistiocytic tumor; CNTK: cellular neurothekeoma; GCTST: giant cell tumor of soft tissue; PM: plexiform myofibroblastoma; LRR: local recurrence rate; LR: local recurrence; IHC: immunohistochemistry; SMA: smooth muscle actin; CCND1: cyclin D1; NSE: neuron-specific enolase; MiTF: microphthalmia transcription factor; PGP9.5: protein gene product 9.5; PRAME: preferentially expressed antigen in melanoma; TFE3: transcription factor E3; MTAP: methylthioadenosine phosphorylase; CDKN2A: cyclin dependent kinase inhibitor 2A; H3-3A: H3.3 histone A; SH3PXD2B: SH3 and PX domains 2B; FER: FER tyrosine kinase. Cellular neurothekeoma (CNTK) is a benign cutaneous neoplasm that most commonly arises in the upper extremities and head and neck of young adults, with a mean age of 25 years and a slight female predominance (30). It typically presents as a slow-growing, painless, solitary papule or nodule, usually measuring less than 2 cm in diameter. Recently, multiple familial CNTKs have been described (31). CNTK and PFHT display significant morphological overlap (32), suggesting that they may represent the same entity. Histologically, CNTK shows a lobular or multinodular growth pattern and consists of nests of epithelioid to spindled cells with abundant eosinophilic cytoplasm. Osteoclast-like giant cells can be seen in 15% of cases (30). Myxoid or hyalinized stromal changes may be found. Perineural or vascular invasion is rarely seen (30). Mitotic activity is generally low and necrosis is typically absent. Atypical features, such as pleomorphism, brisk mitotic activity or infiltration of fat, have also been reported (30, 33). Immunohistochemically, the neoplastic cells are focally positive for CD68 and SMA (30) and diffusely positive for NKI/C3, neuron-specific enolase, S100A6, CD10, microphthalmia transcription factor and protein gene product 9.5 (30, 32, 34-38). In addition, recent studies have demonstrated that most CNTKs are immunopositive for preferentially expressed antigen in melanoma, transcription factor E3, CD138 and CCND1 (39-42). Immunostainings for cytokeratin, epithelial membrane antigen, desmin, S100, SRY-related HMG-box 10, glial fibrillary acidic protein, HMB-45, Melan-A and CD34 are typically negative (30, 34, 37, 40, 43). At the molecular genetic level, the most recurrent copy number alteration is a deletion on 9p21.3, including methylthioadenosine phosphorylase (MTAP) and cyclin dependent kinase inhibitor 2A (CDKN2A) (44). Additionally, somatic mutations of neurofibromin 1 (NF1), phosphoinositide 3-kinase (PI3K), ALK receptor tyrosine kinase (ALK), smoothened, frizzled class receptor (SMO) and erb-b2 receptor tyrosine kinase 3 (ERBB3) have been identified in individual cases (45, 46). The recommended treatment for CNTK is surgical excision with negative margins. Mohs micrographic surgery may also be used to achieve margin control (47). Local recurrence occurs in approximately 14.5% of cases (30). Location seems to be a predictor of local recurrence, especially in the face (30). Notably, atypical histological features are not predictive of local recurrence (30, 33). Although extremely rare, lymph node metastasis has been reported in the literature (48, 49). Further studies and molecular investigation are required to better delineate the relationship between CNTK and PFHT. Giant cell tumor of soft tissue (GCTST) is a locally aggressive mesenchymal neoplasm of intermediate malignancy that primarily occurs in the upper and lower extremities of young to middle-aged adults, with a peak incidence in the fifth decade of life and no sexual predominance (50). It typically presents as a painless, superficial soft tissue mass, with a mean tumor size of 3 cm (51). Histologically, GCTST shows a multinodular architecture and consists of a mixture of round to oval mononuclear cells and osteoclast-like giant cells in a richly vascularized stroma. Unlike PFHT, metaplastic bone formation is present in approximately 40-50% of cases (52, 53). Aneurysmal bone cyst-like changes may be seen. Vascular invasion is found in approximately 32% of cases (53). Mitotic activity is readily observed but necrosis is uncommon. Moreover, high-grade (i.e., malignant) GCTST has been described in the literature (54-57). In contrast to conventional GCTST, malignant GCTST displays increased mitotic activity, nuclear atypia and pleomorphism (54). Immunohistochemically, the mononuclear and osteoclast-like giant cells are positive for CD68, whereas only a few mononuclear cells express SMA. Immunostainings for desmin, S100, lysozyme, CD31 and CD45 are typically negative (50). Cytogenetic analysis displays numerous telomeric associations involving multiple chromosomes (58). At the molecular genetic level, GCTST lacks mutations of the H3.3 histone A (H3-3A) gene that are identified in the vast majority of giant cell tumors of bone (59, 60), suggesting a different pathogenesis. To date, no recurrent genetic alterations have been identified (61, 62). Wide local excision is the mainstay of treatment for GCTST. There is currently no consensus about an adequate margin of excision for GCTST. Local recurrence occurs in 6.2-21% of cases (52, 53). Although rare, distant metastasis or malignant transformation has been reported in the literature (53, 54, 58, 61-63). Plexiform myofibroblastoma (PM), first described by Papke et al. (64) in 2020, is a rare benign mesenchymal neoplasm that primarily occurs in the trunk and neck of children and young adults, with a median age of 9.5 years and no sexual predominance (64). It typically presents as a slow-growing, painless, superficial mass, with a mean tumor size of 2.7±1.7 cm (64). PM can occasionally occur as multiple discontiguous lesions. The median preoperative duration is 6 months (64). PM shows overlapping histological features with fibroblastic variant of PFHT. Histologically, PM is composed of plexiform fascicles of bland fibroblastic/myofibroblastic spindle cells in a variably collagenous stroma. Focal myxoid stromal changes and keloidal hyalinization may be seen. Mitotic activity is absent or minimal and necrosis is absent. Unlike PFHT, PM lacks histiocytoid cells and does not contain admixed osteoclast-like giant cells. Immunohistochemistry demonstrates positivity for SMA, CD34 and desmin in 84%, 54% and 43% of cases, respectively (64). Immunostainings for S100 and β-catenin are typically negative. At the molecular genetic level, an SH3 and PX domains 2B (SH3PXD2B)::FER tyrosine kinase (FER) fusion has been identified in a single case (65). Simple excision is the treatment of choice for PM. Only one of the 16 PM patients who were available for follow-up developed local recurrence, although many tumors were excised with positive margins (64). These results indicate that it is important to avoid overtreatment with unnecessary re-excision even if the surgical margin is positive after initial excision. Unlike PFHT, no distant metastasis has been reported in PM. Clinical Management Recommendations The initial work-up for PFHT involves a thorough history, physical examination and appropriate imaging studies. MRI provides the most accurate information for diagnosis and surgical planning, although ultrasonography is the preferred imaging modality. Once the diagnosis has been confirmed using appropriate imaging and a tissue biopsy, the main modality of management is usually surgical excision. Regular follow-up for at least five years after surgery is recommended to assess local control and development of metastatic disease. Conclusion PFHT is a rare intermediate (locally aggressive) mesenchymal neoplasm that primarily occurs in the upper extremities of children and young adults. MRI exhibits a poorly demarcated, infiltrative lesion in the subcutis, with significant contrast enhancement. PFHT is histologically characterized by a plexiform architecture and a biphasic composition of histiocyte-like cells, often with osteoclast-like giant cells, and spindle cells. Expression of CCND1 and CD10 is frequently observed, although the immunophenotype is rather non-specific. Wide local excision is the mainstay of treatment for PFHT. The prognosis is generally favorable; however, local recurrence is common because of the infiltrative growth pattern. Further investigations are required to better understand the correlation between PFHT and CNTK. Conflicts of Interest The Authors declare no conflicts of interest associated with this article. Authors’ Contributions JN conceived and designed the study, researched the literature and drafted the article. KK and MA critically revised the article. All authors read and approved the final version of the article. Funding This study was supported by the Japan Society for the Promotion of Science KAKENHI Grant Number 26K12071. Artificial Intelligence (AI) Disclosure No artificial intelligence (AI) tools, including large language models or machine learning software, were used in the preparation, analysis, or presentation of this article.